Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used for the treatment of moderate to severe Alzheimer's disease. It works by modulating glutamate signaling, which is thought to be dysregulated in Alzheimer's disease and contributes to excitotoxic neuronal damage. [@reisberg2003]
Mechanism of Action
Memantine provides neuroprotection through unique mechanisms:
NMDA Receptor Modulation: Low-affinity, uncompetitive blocking of NMDA receptors
[Dementia with Lewy Bodies](/diseases/lewy-body-dementia)
[Vascular Dementia](/diseases/vascular-dementia)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[ClinicalTrials.gov](https://clinicaltrials.gov/)
Background
The study of Memantine Nmda Antagonist For Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
References
[Reisberg B, et al, "Memantine in moderate-to-severe Alzheimer's disease." N Engl J Med (2003)](https://pubmed.ncbi.nlm.nih.gov/12672860/)
[Tariot PN, et al, "Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial." JAMA (2004)](https://pubmed.ncbi.nlm.nih.gov/14734594/)
[McShane R, et al, "Memantine for dementia." Cochrane Database Syst Rev (2006)](https://pubmed.ncbi.nlm.nih.gov/16625572/)
[Parsons CG, et al, "Memantine: a NMDA receptor antagonist that improves cognition by rendering normal NMDA receptor transmission." J Neural Transm (2007)](https://pubmed.ncbi.nlm.nih.gov/17237754/)
[Lipton SA, "Paradigm shift in neuroprotective drug development: clinically tolerated NMDA modulation by low-affinity channel blockers." Lancet (1999)](https://pubmed.ncbi.nlm.nih.gov/10543739/)
[Wenk GL, et al, "Memantine as a treatment for Alzheimer's disease: uncoupling efficacy from clinical response." CNS Spectr (2006)](https://pubmed.ncbi.nlm.nih.gov/16575408/)
[Kavirajan H, Schneider LS, "Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials." Lancet Neurol (2007)](https://pubmed.ncbi.nlm.nih.gov/17689146/)
[Gauthier S, et al, "Clinical benefits of memantine in everyday practice." Int J Geriatr Psychiatry (2008)](https://pubmed.ncbi.nlm.nih.gov/18213698/)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2